Researchers used lymphoblastoid cell lines from 589 patients to
identify associations between genetic variants and differential drug
response, as well as the role of ethnicity in drug potency and efficacy
for 28 chemotherapeutic compounds. Patients self-reported their
ethnicity as Hispanic or non-Hispanic/Caucasian.
For many drugs, the variability in drug response appears to
correlate with genetic ancestry and self-reported race. Hispanic and
Caucasian samples exhibited unique results, indicating a complex
relationship between genome and drug response and treatment outcomes.
Notable associations were found for the drug temozolomide, which is used
to treat brain tumors. Other drugs with results that suggest an
association include etoposide and mitomycin, but the authors note that
these results should be viewed as hypothesis generation.
"Based on the cell lines of hundreds of individuals, our research
suggests that the genetic ancestry of a person is strongly related to a
person's response to anticancer drug treatment," said John Jack, PhD,
lead author and research scientist at North Carolina State University.
"The developing field of "Personalized" or "precision medicine" will
leverage these types of data to help inform a doctor's decision on
selecting the optimal drug and dose for each patient."
"This elegant study addresses questions on the role of ethnicity in
drug response and the part played by individual genes in drug response."
No comments:
Post a Comment